NCT03566446View on ClinicalTrials.gov

CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

April 30, 2021

Conditions
Myeloproliferative Neoplasm, UnclassifiableEssential ThrombocythemiaMyelofibrosis
Interventions
BIOLOGICAL

CALRLong36 peptide

200 ug CALRLong36 peptide in water mixed with 500ul montanide

Trial Locations (1)

2730

Herlev Hospital, Herlev

All Listed Sponsors
lead

Inge Marie Svane

OTHER

NCT03566446 - CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter